TKNO trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TKNO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Alpha Teknova, Inc. (TKNO) has a Wall Street consensus price target of N/A, based on estimates from 3 covering analysts. The company has a market capitalization of $308M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, TKNO trades at a trailing P/E of -18.0x. Analysts expect EPS to grow -4.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AZTAAzenta, Inc. | $1.2B | $25.50 | $45.00 | +76.5% | Buy | 56.8x | 12 |
BRKRBruker Corporation | $9.3B | $60.91 | $50.17 | -17.6% | Buy | 28.8x | 32 |
NTRANatera, Inc. | $37.5B | $261.91 | $258.78 | -1.2% | Buy | — | 27 |
PACBPacific Biosciences of California, Inc. | $512M | $1.65 | $1.00 | -39.4% | Buy | — | 18 |
FLGTFulgent Genetics, Inc. | $567M | $19.96 | $15.00 | -24.8% | Buy | — | 9 |
CRLCharles River Laboratories International, Inc. | $10.4B | $215.75 | $214.14 | -0.7% | Buy | 19.4x | 37 |
MEDPMedpace Holdings, Inc. | $15.1B | $527.07 | $498.86 | -5.4% | Hold | 31.0x | 19 |
ICLRICON Public Limited Company | $13.0B | $169.86 | $160.08 | -5.8% | Buy | 16.0x | 30 |
RVTYRevvity, Inc. | $12.6B | $113.02 | $110.57 | -2.2% | Buy | 21.5x | 29 |
QGENQiagen N.V. | $8.1B | $39.41 | $43.95 | +11.5% | Hold | 16.2x | 30 |
Quick answers to the most common questions about buying TKNO stock.
The consensus price target for TKNO is $N/A, close to the current price of $5.75 (N/A% implied move). Based on 3 analyst estimates, the stock appears fairly valued near current levels.
TKNO has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
TKNO's current price is $5.75 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for TKNO, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
TKNO is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TKNO stock forecast based on 3 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
TKNO appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TKNO analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.